top1288
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2015 (NCT02463045)
Timeline
Indications
Studied for
Mechanism of action
- MAP kinase p38 betaINHIBITOR
MAPK11 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- top1288
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02888379 | Phase 2 | Sep 1, 2016 | Topivert Pharma Ltd, University of Oxford |
| NCT02463045 | Phase 1 | May 1, 2015 | Topivert Pharma Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Topivert Pharma Ltd | For profit | 2 | 2 | 2 | 2015 |
| University of Oxford | Academic/Hospital | 1 | 0 | 1 | 2016 |
2 organizations
Page 1 / 1